Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic...

Area of Science:

• Oncology
• Clinical Research
• Cancer Therapy

Background:

• Local consolidative therapy (LCT) is being investigated for metastatic cancers, but its efficacy varies by cancer type.
• Metastatic non-small cell lung cancer (mNSCLC) is a significant health concern, necessitating effective treatment strategies.

Purpose of the Study:

• To systematically review and meta-analyze the efficacy of LCT compared to systemic therapy alone in patients with mNSCLC.
• To evaluate the impact of LCT on progression-free survival (PFS), overall survival (OS), and adverse events (AEs) in mNSCLC.

Main Methods:

• Systematic review and meta-analysis of 7 eligible studies, including randomized and propensity-matched retrospective trials.
• Inclusion criteria: histologic confirmation of mNSCLC, comparison of LCT (irradiation/surgery) vs. no LCT, and data on PFS, OS, and/or AEs.
• Statistical analysis using Mantel-Haenszel fixed-effect or random-effect models based on heterogeneity (I²).

Main Results:

• LCT demonstrated a significant improvement in PFS (HR 0.37) and OS (HR 0.53) for all mNSCLC patients.
• Patients with oligometastatic disease (OMD) showed even greater benefits in PFS (HR 0.30) and OS (HR 0.41) with LCT.
• LCT was not associated with an increased risk of high-grade adverse events (OR 1.28).

Conclusions:

• LCT may enhance PFS and OS in mNSCLC patients without a higher risk of severe adverse events.
• Further investigation is required for polymetastatic mNSCLC, and findings cannot be generalized to other cancer types.
• Future trials should focus on specific tumor biology interactions with systemic agents for enhanced clarity and applicability.